Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Posts 5 Percent Decline in Revenues for Fiscal Q3

NEW YORK (GenomeWeb News) - Accelrys today reported declining revenues for its fiscal third quarter, accompanied by a larger net loss and a double-digit decrease in general and administrative spending.
For the three months ended Dec. 31, 2007, revenue fell 5 percent to $19.6 million from $20.7 million in the comparable period of the prior year.
The company said in a statement that the decrease in revenue was due to a fall-off in orders for “de-emphasized products,” which was partially offset by growth in sales for its Pipeline Pilot “scientific operating platform.” Accelrys said that a one-time “service revenue benefit” of $300,000 in the third quarter of the prior fiscal year also contributed to the year-over-year revenue decline.
Mark Emkjer, president and CEO of Accelrys, said in a statement that orders for Pipeline Pilot “increased substantially” during the quarter, and that two undisclosed pharmaceutical companies ”significantly increased their investments” in the platform.
During a conference call today to discuss the third-quarter earnings, Accelrys CFO Rick Russo noted that the company recognizes its revenues ratably, and therefore expects the increase in orders in the third quarter to lead to an uptick in revenues for the company's fourth fiscal quarter, which ends March 31.  
Accelrys's quarterly net loss grew by 9 percent to $1.2 million, or $0.05 per share, from $1.1 million, or $0.04 per share, in the prior-year quarter.
Spending on product development fell by 4 percent to $4.5 million from $4.7 million, while sales and marketing expenses grew by nearly 8 percent to $9.6 million from $8.9 million.
Accelrys cut its general and administrative costs by 17 percent to $3.4 million from $4.1 million in the comparable quarter of 2007.
As of Dec. 31, Accelrys had cash, cash equivalents, restricted cash, and marketable securities of $65.8 million.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.